UCP2 and metabolic dysfunction-associated steatotic liver disease: Subsequent studies should focus on the temporal dynamics of the inhibitory effect of geniposide on UCP2, determining whether geniposide exerts this inhibitory effect during the early stage of NAFLD, when ROS levels are reduced, or during the late stage of NAFLD, when a substantial amount of ATP is consumed.